Shots:
- Ventus Therapeutics has entered a multi-year collaboration with Genentech to discover and optimize novel small-molecule drugs for major diseases using its ReSOLVE platform
- As per the deal, Ventus will utilize its ReSOLVE platform to identify small-molecule leads for multiple targets, while Genentech will be responsible for preclinical, clinical, and commercial development. Ventus will receive upfront and milestone payments exceeding $460M, plus tiered royalties on net sales
- ReSOLVE integrates AI, ML, and structural biology to map dynamic water networks in protein pockets, enabling faster and more cost-effective lead identification and optimization through its hydrocophore technology
Ref: Ventus Therapeutics | Image: Ventus Therapeutics & Genentech| Press Release
Related News:- Genentech Reports the US FDA’s Approval of Gazyva (Obinutuzumab) to Treat Lupus Nephritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
